ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Lumiracoxib ['Prexige'], a novel cyclo-oxygenase (COX)-2 inhibitor provides benefit for patients with osteoarthritis, according to studies presented at the recent Annual Congress of the European League Against Rheumatism (EULAR) [Lisbon, Portugal; June 2003]. The results of a pivotal 13-week phase III study showed that lumiracoxib was as effective as celecoxib in improving pain and function in patients with osteoarthritis of the knee. The long-term efficacy of lumiracoxib was demonstrated for the first time in a 1-year study, with sustained improvements in pain and function. Other studies presented at the meeting showed that lumiracoxib provided rapid relief of osteoarthritis pain, with significant improvements observed as early as 3 hours after administration of the first dose.

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

摘要:

Atazanavir ['Reyataz'], a once-daily azapeptide protease inhibitor (PI), is effective when used in salvage therapy regimens for patients with HIV infections, according to two studies presented at the 2nd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment [Paris, France; July 2003]. In the first study, ritonavir-boosted atazanavir demonstrated efficacy comparable to that of the standard lopinavir/ritonavir combination in heavily pretreated patients, but was less likely to adversely affect serum lipid levels. In the other study, atazanavir was less effective than lopinavir/ritonavir in the overall patient population, who had failed one or more previous PI-containing regimens, but demonstrated equivalence when baseline PI-resistance was taken into account. As in the first study, atazanavir had a significantly improved lipid profile, compared with lopinavir/ritonavir, suggesting that atazanavir-based regimens may be preferable to standard therapy in patients whose lipid levels are of concern.

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:2003

数据来源: ADIS